Overview

Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test the safety and efficacy of brentuximab vedotin in patients with acute skin graft-versus-host disease (GVHD)
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies
Antibodies, Monoclonal
Brentuximab Vedotin
Immunoconjugates
Immunoglobulins